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Heart failure is a common clinical condition associated with 
high morbidity and mortality rate despite significant im-
provements in pharmacotherapy and implementation of 
medical procedures. Patients with heart failure are at an in-
creased risk of developing arterial and venous thrombosis, 
which contribute to the high rate of adverse events and fa-
tal outcomes. Many heart failure patients routinely receive 
antithrombotic therapy due to the presence of a specific 
indication for its use, like ischemic heart disease or atrial 
fibrillation. However, there is no solid evidence to support 
the routine use of antithrombotic agents in all heart failure 
patients. This article reviews the evidence for using anti-
thrombotic therapy in heart failure patients.
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Heart failure (HF) is a complex clinical syndrome caused by 
a number of different disorders that impair the heart mus-
cle’s ability to maintain adequate blood flow to meet the 
body’s metabolic needs. Research and advances in man-
aging HF so far have been mainly focused on improving 
the neurohormonal imbalance and assisting the myocar-
dium to increase the cardiac output with different types of 
devices. Over the last couple of decades there have been 
considerable improvements in pharmacotherapy and 
medical procedures for treating HF, such as the introduc-
tion of angiotensin-converting enzyme inhibitors (ACEIs), 
angiotensin receptor blockers (ARBs), beta blockers, aldos-
terone antagonists, If channel blocker ivabradine, cardiac 
resynchronization therapy (CRT), and ventricular assist de-
vices (VADs). However, HF is still a major public health is-
sue associated with increased morbidity and mortality (1). 
Because of the broad spectrum of its clinical presentations, 
aging of the population, and different comorbidities and 
treatment options, HF treatment represents a considerable 
challenge. Patients with HF are at an increased risk of de-
veloping arterial and venous thrombosis, which contrib-
ute to the high rate of adverse events and fatal outcomes 
(2-5). Further research should clarify whether routine use 
of antithrombotic agents brings clinical benefit to all HF 
patients.
ThroMboeMbolic burDen of hf
HF patients have been reported to have increased plate-
let reactivity, reduced platelet survival time, and increased 
mean platelet volume (6-8). They have also been shown to 
have increased concentrations of fibrinogen and D-dim-
er, whose levels correlate with HF severity (9). Postmortem 
studies have shown that in patients with HF acute coro-
nary incident represents an underrated cause of death. In 
the Assessment Of Treatment With Lisinopril And Survival 
(ATLAS) trial, acute coronary finding on autopsy was pres-
ent in 33% of patients classified as having died from sud-
den cardiac death (5). Furthermore, the Optimal Trial in 
Myocardial Infarction with Angiotensin II Antagonist Losar-
tan (OPTIMAAL) (10) has shown that an acute myocardial 
infarction was present in 55% and 81% of autopsies of HF 
patients classified as having died from arrhythmia and HF 
progression, respectively. As only 19% of patients had un-
dergone autopsy, it is possible that this number was even 
higher (10). The prevalence of acute coronary incidents in 
HF patients is probably underestimated due to several 
factors such as HF itself, myocardial hybernation, cardiac 
denervation, or silent ischemia with co-existing diabe-
tes, which mask the appearance of acute coronary 
syndrome. HF is also a common cause of ischemic stroke 
(11). In the population-based Framingham Heart Study, 
the relative risk of stroke in HF patients compared to those 
without HF was 4.1 for men and 2.8 for women (12). HF pa-
tients also have a high rate of stroke recurrence and mor-
tality after stroke (13,14). Besides this, HF is an independent 
predictor of venous thromboembolism (VTE) (2,15-17). Pa-
tients with left ventricular ejection fraction (LVEF) of 20%-
44% and less than 20% had a 2.8 and 38.3 times higher 
risk of developing VTE, respectively, meaning that sever-
ity of HF increased the risk of VTE (17). An increased risk of 
VTE was present in hospitalized HF patients compared to 
patients without HF, with a relative risk of 2.15 for pulmo-
nary embolism and 1.21 for VTE (15). Having this in mind, 
chronic antithrombotic therapy seems a very rational treat-
ment for these patients. Limited data on HF patients with 
preserved ejection fraction suggest that their risk of stroke 
is similar to that in HF patients with reduced ejection frac-
tion, but the risk of thromboembolism is uncertain (18,19).
WhaT Do guiDelineS Say?
In 2012 European Society of Cardiology (ESC) issued new 
guidelines for treating HF, which state that other than in pa-
tients who have atrial fibrillation (AF) there is no evidence 
that oral anticoagulants reduce mortality and morbidity 
compared to placebo or aspirin in both HF with reduced 
and with preserved ejection fraction (1). Joint guidelines 
of American College of Cardiology Foundation (ACCF) and 
American Heart Association (AHA) for the management of 
HF from 2013 also do not recommend chronic anticoagu-
lation therapy for patients without AF, a prior thromboem-
bolic event, or an intraventricular thrombus (20). They also 
state that there is no evidence to use antiplatelet therapy 
in patients with HF in the absence of a specific indication 
(20). Similar recommendations have also been issued by 
the Joint Consensus Document from the ESC Heart Failure 
Association and the ESC Working Group on Thrombosis in 
2012 (21) and the 2012 American College of Chest Physi-
cians guidelines (22).
PaThoPhySiology of VenoarTerial ThroMboSiS 
in hf
Among risk factors for thrombotic events in HF are all 
three segments of Virchow’s triad (blood stasis, blood 
vessel dysfunction, blood hypercoagulability). Reduction 
in blood flow and increase in the chance of intracardiac 
thrombus formation are caused by myocardial contractil-
ity dysfunction and enlargement of heart chambers (23). 
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Abnormalities of the vessel walls in HF failure are caused 
by neurohormonal activation, inflammation, and en-
dothelial dysfunction. HF impairs nitric oxide synthesis, 
which results in oxidative stress and promotes monocyte 
and platelet adhesion to the endothelium (24). Endothe-
lial dysfunction in both arterial and venous system is a re-
sult of the distension of vessel wall and hypoxia. It is also 
enhanced by the increase in von Willebrandt factor con-
centration, soluble thrombomodulin concentration, and 
E-selectin levels (23,25,26). Activation of the sympathetic 
nervous system and of the renin-angiotensin-aldosterone 
system also plays a role in the enhanced thrombogenesis 
in HF as they increase β-thromboglobulin, platelet surface 
P-selectin, and plasminogen activator inhibitor-1 concen-
tration levels, and thus, increase platelet aggregation and 
reduce fibrinolysis (25,26). Furthermore, low output and 
blood stasis contribute to the reduced renal clearance of 
procoagulation factors (27).
On the other hand, hemostatic disorder in HF patients 
might be also caused by comorbidities and medication. 
Patients with severe right HF can also develop congestive 
hepatopathy with impaired hepatic synthesis of coagula-
tion factors II, V, VII, IX, and X, causing international normal-
ized ratio (INR) prolongation and bleeding diathesis.
STuDieS on anTiThroMboTic agenTS in hf in SinuS 
rhyThM
retrospective observational analyses
Aspirin is the most widely used antithrombotic drug in HF 
patients in sinus rhythm, as ischemic heart disease is the 
most common condition that causes myocardial dysfunc-
tion (28). As there is very little solid evidence that long-
term aspirin usage brings clinical benefit in both primary 
and secondary prevention of vascular events, its use in the 
setting of HF with sinus rhythm is questionable. Further-
more, aspirin in HF patients has never been directly com-
pared against placebo in a randomized trial. At present 
there is no sufficient evidence to support the use of aspirin 
in all HF patients. The potential harm of aspirin use in HF 
patients lies predominately in its possible interaction with 
ACEIs, as observed in the post-hoc analysis of the Study 
Of Left Ventricular Dysfunction (SOLVD), where aspirin was 
found to decrease the survival benefit of ACEIs (29). This 
interaction is believed to be caused by aspirin’s effect on 
prostaglandin synthesis in the vessel wall (30,31). A sys-
tematic overview of data for 22,060 patients (mainly with 
known vascular disease) from six long-term randomized 
trials of ACEIs found no solid evidence that benefit of ACEI 
therapy was reduced when it was added to aspirin (32).
A possible interaction between aspirin and beta blockers 
was addressed in a retrospective analysis of 293 patients 
enrolled in a randomized, placebo-controlled trial of carve-
dilol. Among patients receiving carvedilol, those on aspirin 
therapy had less improvement in LVEF compared to aspirin 
nonusers and this effect was dose related. The mechanism 
behind this interaction is unknown (33).
The second most utilized antiplatelet agent today – clopi-
dogrel, a second generation thienopiridine that does not 
inhibit prostaglandin production, was found to be a bet-
ter antiplatelet option in HF patients than aspirin. This was 
shown by direct comparison in small randomized trials 
demonstrating that patients on clopidogrel had lower val-
ues of natriuretic peptides, better arterial function prop-
erties, and higher oxygen uptake during exercise testing 
(34-37). Bonde et al showed in a registry analysis of 50,000 
patients hospitalized for the first myocardial infarction 
who were not treated with percutaneous coronary inter-
vention that patients without HF had similar survival with 
or without clopidogrel, while patients with HF on clopi-
dogrel had a significantly better survival compared to HF 
patients without clopidogrel (38). There is a lack of data on 
HF patients treated with newer, more potent antiplatelet 
agents – prasugrel and ticagrelor, as they have not been 
adequately tested in HF patients yet.
Analyses of the Spanish REDINSOR registry, which includ-
ed 2263 HF patients with left ventricular ejection fraction 
≤35% and sinus rhythm without other anticoagulation in-
dications, showed no significant difference in total mortal-
ity and stroke incidence between patients who received 
anticoagulants (26%) and those who did not. Multivari-
ate analysis, however, showed a decreased incidence in 
the combined endpoint of cardiovascular events (death, 
heart transplantation, coronary revascularization, hospi-
talization) in patients receiving anticoagulant therapy (39). 
Newer, available oral anticoagulants such as dabigatran – a 
direct thrombin inhibitor, or apixaban and rivaroxaban – 
factor Xa inhibitors, have not been specifically tested in pa-
tients with HF, especially in those in sinus rhythm.
important randomized controlled trials on 
antithrombotic agents in hf patients in sinus rhythm
Warfarin/Aspirin Study in Heart Failure (WASH) was a 
randomized study with 279 enrolled patients as-
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signed to three groups – warfarin with target INR 2.5, aspi-
rin 300 mg/d, and a group with no antithrombotic therapy. 
Mean follow-up period was 27 months. No difference was 
found in the primary endpoint (death, nonfatal myocardial 
infarction [MI], nonfatal stroke) between study groups. Pa-
tients on aspirin were twice as likely to be hospitalized due 
to cardiovascular cause or die during the first 12 months of 
follow-up compared to patients on warfarin. Around 75% 
of patients were male, 60% had an ischemic heart disease, 
and 4%-7% had atrial fibrillation (40).
Heart failure Long-term Antithrombotic study (HELAS) was 
prematurely stopped due to slow enrollment after having 
enrolled 197 patients out of the planned 6500. Patients 
with ischemic heart disease (n = 115) were randomized to 
325 mg/d aspirin or warfarin (target INR 2.5-3.0), while 82 
patients without ischemic heart disease were randomized 
to placebo or warfarin group (target INR 2.5-3.0). Patients 
were followed for a mean of 18.5 to 21.9 months. The sam-
ple was too small to detect any differences between the 
study groups in the primary composite endpoint and its 
components – non fatal MI, stroke, death, peripheral em-
bolism, pulmonary embolism, rehospitalization, and HF 
worsening (41).
Warfarin and Antiplatelet Therapy in Chronic Heart Failure 
(WATCH) trial recruited 1587 patients with LVEF<35% and 
sinus rhythm. Patients were randomized to receive 162 
mg/d aspirin, 75/d clopidogrel (double-blind fashion), and 
open label warfarin (target INR 2.5-3.0). Mean follow-up 
period was 1.9 years. There was no difference in compos-
ite primary endpoints (death, nonfatal MI, nonfatal stroke) 
between the study arms. Warfarin was associated with a 
reduced rate of stroke, but also with a higher rate of bleed-
ing events compared only with clopidogrel group, but not 
with aspirin group. This trial did not show that warfarin or 
clopidogrel were superior to aspirin in HF patients in sinus 
rhythm (42).
Warfarin vs Aspirin in patients with Reduced Cardiac Ejec-
tion Fraction (WARCEF) trial was a large, randomized, dou-
ble-blind, double-dummy trial that evaluated the efficacy 
of 325 mg/d aspirin vs warfarin with a target INR of 2 to 3.5. 
The study enrolled 2305 patients and only 43% had evi-
dence of underlying ischemic heart disease. Mean follow-
up was 3.5 years (range, 1-6 years). Compared to aspirin, 
warfarin did not significantly reduce the rate of the pri-
mary outcome (composite of ischemic stroke, intracere-
bral bleeding, and all cause mortality). A time-varying 
analysis showed a decreasing hazard ratio in warfa-
rin group compared to aspirin and a significant benefit by 
the fourth year of follow-up. Warfarin group also had a 48% 
lower rate of ischemic stroke, but at the cost of significantly 
increased rate of major and minor bleeding events. Due 
to the low rate of ischemic stroke compared to bleeding 
events, the benefit of warfarin over aspirin in all HF patients 
was not demonstrated. Furthermore, patients on warfarin 
had a higher risk for hospitalization as opposed to WASH 
and WATCH study, where patients on aspirin had more 
hospitalizations. WARCEF is so far the largest randomized 
trial to address the usefulness of antithrombotic agents in 
HF in sinus rhythm (43). A subgroup analysis of WARCEF 
showed that in patients under 60 years, warfarin improved 
outcomes over aspirin with or without inclusion of major 
hemorrhage. For patients ≥60 years, there was no differ-
ence, but the aspirin group had significantly better out-
comes when major hemorrhage was included (44).
anTiThroMboTic agenTS in acuTe hf
Acute decompensated HF further increases the risk for 
thromboembolism (45) and these patients should be re-
ceiving anticoagulation therapy as VTE prophylaxis until 
compensated and mobilized. Whether antiplatelet therapy 
could improve prognosis in acute HF is not clear. Kozdag et 
al showed on 580 patients discharged from hospital after 
acute decompensated HF (63% with coronary artery dis-
ease) that patients on clopidogrel had statistically signifi-
cant decrease in cardiac mortality compared to patients 
who did not take clopidogrel (46).
fuTure DirecTionS anD PerSPecTiVeS
Due to population aging and increased survival of patients 
with cardiovascular diseases, prevalence of HF will contin-
ue to increase (11). The debate about how antithrombot-
ic agents can improve outcomes of HF patients in sinus 
rhythm is still open. It would certainly be interesting to test 
the efficacy of antithrombotic therapy not only on top of, 
but also against contemporary optimal medical therapy 
for HF. However, for ethical reasons this comparison will 
probably never be done.
Antithrombotic therapy in HF is intensively investigated by 
ongoing trials. A study (NCT01534026) investigating the 
effect of withdrawing aspirin compared to its use will ad-
dress the need to prescribe aspirin to non-ischemic HF pa-
tients in sinus rhythm (47). Clopidogrel Vs Aspirin in Chron-
ic Heart Failure (CACHE), a non-blinded, large randomized 
controlled trial (ISRCTN22153967) plans to enroll 3000 
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patients with HF in sinus rhythm and investigate wheth-
er aspirin 75 mg/d, compared to clopidogrel 75 mg/d, in-
creases mortality and the number of HF hospitalizations, 
and reduces the quality of life. The planned mean duration 
of follow-up is 3.8 years and the study is expected to end 
in August 2016 (48). COMMANDER HF trial (NCT01877915) 
is planned to assess the effectiveness and safety of rivar-
oxaban compared to placebo in reducing the risk of death, 
myocardial infarction, or stroke in 5000 HF patients with 
significant coronary artery disease following a recent hos-
pitalization for HF exacerbation (49).
concluSion
To date, there has been no solid evidence to support the 
use of antithrombotic agents in all HF patients despite 
the fact that HF is associated with hypercoagulability 
and increased platelet activation. Treating chronic HF pa-
tients with antithrombotic agents without a proper indi-
cation such as recent coronary stenting, atrial fibrillation, 
implanted prosthetic valve, or ventricular assist device, is 
controversial, and routine use of these agents is not rec-
ommended for now in these patients. As HF patients are 
a heterogenous population, future trials should be care-
fully designed. The risk-benefit ratio in HF patients in sinus 
rhythm could be improved using platelet function test-
ing and thromboelastometry. Also, adequately designed, 
large-scale randomized placebo-controlled trials involving 
new antiplatelet and new oral anticoagulant agents are 
also warranted to clarify the necessity of giving antithrom-
botic agents to all HF patients.
funding None.
ethical approval Not required.
Declaration of authorship All authors contributed to making of this review 
article, coordinated and guided by the first author.
competing interests DM is Dean of the University of Zagreb School of 
Medicine, one of the owners of the Croatian Medical Journal. To ensure that 
any possible conflict of interest relevant to the journal has been addressed, 
this article was reviewed according to best practice guidelines of interna-
tional editorial organizations. All authors have completed the Unified Com-
peting Interest form at www.icmje.org/coi_disclosure.pdf (available on re-
quest from the corresponding author) and declare: no support from any 
organization for the submitted work; no financial relationships with any or-
ganizations that might have an interest in the submitted work in the previ-
ous 3 years; no other relationships or activities that could appear to have 
influenced the submitted work.
references
1 McMurray JJ, adamopoulos S, anker SD, auricchio a, böhm M, 
Dickstein K, et al. eSc guidelines for the diagnosis and treatment 
of acute and chronic heart failure 2012: The Task force for the 
Diagnosis and Treatment of acute and chronic heart failure 2012 
of the european Society of cardiology. Developed in collaboration 
with the heart failure association (hfa) of the eSc. eur heart 
J. 2012;33:1787-847. Medline:22611136 doi:10.1093/eurheartj/
ehs104
2 Samama MM. an epidemiologic study of risk factors for deep 
vein thrombosis in medical outpatients: the Sirius study. arch 
intern Med. 2000;160:3415-20. Medline:11112234 doi:10.1001/
archinte.160.22.3415
3 Sorensen hT, horvath-Puho e, lash Tl, christiansen cf, Pesavento 
r, Pedersen l, et al. heart disease may be a risk factor for 
pulmonary embolism without peripheral deep venous thrombosis. 
circulation. 2011;124:1435-41. Medline:21900083 doi:10.1161/
circulaTionaha.111.025627
4 Pullicino PM, halperin Jl, Thompson Jl. Stroke in patients with 
heart failure and reduced left ventricular ejection fraction. 
neurology. 2000;54:288-94. Medline:10668685 doi:10.1212/
Wnl.54.2.288
5 uretsky bf, Thygesen K, armstrong PW, cleland Jg, horowitz JD, 
Massie bM, et al. acute coronary findings at autopsy in heart 
failure patients with sudden death: results from the assessment 
of treatment with lisinopril and survival (aTlaS) trial. circulation. 
2000;102:611-6. Medline:10931799 doi:10.1161/01.cir.102.6.611
6 Mehta J, Mehta P. Platelet function studies in heart disease. Vi. 
enhanced platelet aggregate formation activity in congestive 
heart failure: inhibition by sodium nitroprusside. circulation. 
1979;60:497-503. Medline:455612 doi:10.1161/01.cir.60.3.497
7 o’connor cM, gurbel Pa, Serebruany Vl. usefulness of soluble 
and surface-bound P-selectin in detecting heightened platelet 
activity in patients with congestive heart failure. am J cardiol. 
1999;83:1345-9. Medline:10235093 doi:10.1016/S0002-
9149(99)00098-3
8 Serebruany V, McKenzie M, Meister a, fuzaylov S, gurbel P, atar D, 
et al. Whole blood impedance aggregometry for the assessment of 
platelet function in patients with congestive heart failure (ePcoT 
Trial). eur J heart fail. 2002;4:461-7. Medline:12167384 doi:10.1016/
S1388-9842(02)00026-0
9 alehagen u, Dahlström u, lindahl Tl. elevated D-dimer level is an 
independent risk factor for cardiovascular death in out-patients 
with symptoms compatible with heart failure. Thromb haemost. 
2004;92:1250-8. Medline:15583730
10 orn S, cleland Jg, romo M, Kjekshus J, Dickstein K. recurrent 
infarction causes the most deaths following myocardial infarction 
with left ventricular dysfunction. am J Med. 2005;118:752-8. 
Medline:15989909 doi:10.1016/j.amjmed.2005.02.010
11 go aS, Mozaffarian D, roger Vl, benjamin eJ, berry JD, blaha MJ, et 
al. heart disease and stroke statistics–2014 update: a report from 
the american heart association. circulation. 2014;129:e28-292. 
Medline:24352519 doi:10.1161/01.cir.0000441139.02102.80
12 Kannel Wb, Wolf Pa, Verter J. Manifestations of coronary 
disease predisposing to stroke. The framingham study. 
JaMa. 1983;250:2942-6. Medline:6227757 doi:10.1001/
ADVANCED HEART FAILURE 626 Croat Med J. 2014;55:621-7
www.cmj.hr
jama.1983.03340210040022
13 Petty gW, brown rD Jr, Whisnant JP, Sicks JD, o’fallon WM, 
Wiebers Do. Survival and recurrence after first cerebral infarction: 
a population-based study in rochester, Minnesota, 1975 through 
1989. neurology. 1998;50:208-16. Medline:9443482 doi:10.1212/
Wnl.50.1.208
14 Sacco rl, Shi T, Zamanillo Mc, Kargman De. Predictors of mortality 
and recurrence after hospitalized cerebral infarction in an urban 
community: the northern Manhattan Stroke Study. neurology. 
1994;44:626-34. Medline:8164815 doi:10.1212/Wnl.44.4.626
15 beemath a, Stein PD, Skaf e, al Sibae Mr, alesh i. risk of venous 
thromboembolism in patients hospitalized with heart failure. 
am J cardiol. 2006;98:793-5. Medline:16950187 doi:10.1016/j.
amjcard.2006.03.064
16 cogo a, bernardi e, Prandoni P, girolami b, noventa f, Simioni P, et 
al. acquired risk factors for deep-vein thrombosis in symptomatic 
outpatients. arch intern Med. 1994;154:164-8. Medline:8285811 
doi:10.1001/archinte.1994.00420020066008
17 howell MD, geraci JM, Knowlton aa. congestive heart failure and 
outpatient risk of venous thromboembolism: a retrospective, case 
control study. J clin epidemiol. 2001;54:810-6. Medline:11470390 
doi:10.1016/S0895-4356(00)00373-5
18 Solomon SD, anavekar n, Skali h, McMurray JJ, Swedberg K, 
yusuf S, et al. influence of ejection fraction on cardiovascular 
outcomes in a broad spectrum of heart failure patients. 
circulation. 2005;112:3738. Medline:16330684 doi:10.1161/
circulaTionaha.105.561423
19 Zile Mr, gaasch Wh, anand iS, haass M, little Wc, Miller ab, et 
al. Mode of death in patients with heart failure and a preserved 
ejection fraction: results from the irbesartan in heart failure 
With Preserved ejection fraction Study (i-Preserve) trial. 
circulation. 2010;121:1393. Medline:20231531 doi:10.1161/
circulaTionaha.109.909614
20 yancy cW, Jessup M, bozkurt b, butler J, casey De Jr, Drazner 
Mh, et al. 2013 accf/aha guideline for the management of 
heart failure: a report of the american college of cardiology 
foundation/american heart association Task force on Practice 
guidelines. J am coll cardiol. 2013;62:e147-239. Medline:23747642 
doi:10.1016/j.jacc.2013.05.019
21 lip gy, Ponikowski P, andreotti f, anker SD, filippatos g, homma 
S, et al. Thrombo-embolism and antithrombotic therapy for heart 
failure in sinus rhythm. a joint consensus document from the 
eSc heart failure association and the eSc Working group on 
Thrombosis. eur J heart fail. 2012;14:681-95. Medline:22611046 
doi:10.1093/eurjhf/hfs073
22 Vandvik Po, lincoff aM, gore JM, gutterman DD, Sonnenberg 
fa, alonso-coello P, et al. Primary and secondary prevention 
of cardiovascular disease: antithrombotic Therapy and 
Prevention of Thrombosis, 9th ed: american college of chest 
Physicians evidence-based clinical Practice guidelines. chest. 
2012;141:e637S.
23 lip gy, gibbs cr. Does heart failure confer a hypercoagulable 
state? Virchow’s triad revisited. J am coll cardiol. 1999;33:1424-6. 
Medline:10193748
24 fischer D, rossa S, landmesser u, Spiekermann S, engberding n, 
hornig b, et al. endothelial dysfunction in patients with chronic 
heart failure is independently associated with increased incidence 
of hospitalization, cardiac transplantation, or death. eur heart J. 
2005;26:65-9. Medline:15615801 doi:10.1093/eurheartj/ehi001
25 caldwell Jc, Mamas Ma, neyses l, garratt cJ. What are the 
thromboembolic risks of heart failure combined with chronic 
or paroxysmal af? J card fail. 2010;16:340-7. Medline:20350702 
doi:10.1016/j.cardfail.2009.12.004
26 Jug b, Vene n, Salobir bg, Sebestjen M, Sabovic M, Keber i. 
Procoagulant state in heart failure with preserved left ventricular 
ejection fraction. int heart J. 2009;50:591-600. Medline:19809208 
doi:10.1536/ihj.50.591
27 Mackman n. new insights into the mechanisms of venous 
thrombosis. J clin invest. 2012;122:2331-6. Medline:22751108 
doi:10.1172/Jci60229
28 Kjekshus J, apetrei e, barrios V, böhm M, cleland Jg, cornel Jh, et 
al. corona group. rosuvastatin in older patients with systolic 
heart failure. n engl J Med. 2007;357:2248-61. Medline:17984166 
doi:10.1056/neJMoa0706201
29 al-Khadra aS, Salem Dn, rand WM, udelson Je, Smith JJ, Konstam 
Ma. antiplatelet agents and survival: a cohort analysis from the 
Studies of left Ventricular Dysfunction (SolVD) trial. J am coll 
cardiol. 1998;31:419-25. Medline:9462588 doi:10.1016/S0735-
1097(97)00502-0
30 hall D, Zeitler h, rudolph W. counteraction of the vasodilator 
effects of enalapril by aspirin in severe heart failure. J am coll 
cardiol. 1992;20:1549-55. Medline:1452929 doi:10.1016/0735-
1097(92)90449-W
31 Meune c, Mahé i, Mourad JJ, cohen-Solal a, levy b, Kevorkian 
JP, et al. aspirin alters arterial function in patients with chronic 
heart failure treated with ace inhibitors: a dose-mediated 
deleterious effect. eur J heart fail. 2003;5:271-9. Medline:12798824 
doi:10.1016/S1388-9842(03)00006-0
32 Teo KK, yusuf S, Pfeffer M, Torp-Pedersen c, Kober l, hall a, et 
al. effects of long-term treatment with angiotensin-converting-
enzyme inhibitors in the presence or absence of aspirin: a 
systematic review. lancet. 2002;360:1037-43. Medline:12383982 
doi:10.1016/S0140-6736(02)11138-X
33 lindenfeld J, robertson aD, lowes bD, bristow Mr. Mocha 
(Multicenter oral carvedilol heart failure assessment) 
investigators. aspirin impairs reverse myocardial remodeling in 
patients with heart failure treated with beta-blockers. J am coll 
cardiol. 2001;38:1950. Medline:11738299 doi:10.1016/S0735-
1097(01)01641-2
34 Meune c, Wahbi K, fulla y, cohen-Solal a, Duboc D, Mahé i, et 
627Miličić et al: Antithrombotics in heart failure
www.cmj.hr
al. effects of aspirin and clopidogrel on plasma brain natriuretic 
peptide in patients with heart failure receiving ace inhibitors. 
eur J heart fail. 2007;9:197-201. Medline:16914369 doi:10.1016/j.
ejheart.2006.06.003
35 Jug b, Sebestjen M, Sabovic M, Keber i. clopidogrel is associated 
with a lesser increase in nT-probnP when compared to aspirin in 
patients with ischemic heart failure. J card fail. 2006;12:446-51. 
Medline:16911911 doi:10.1016/j.cardfail.2006.04.003
36 Meune c, Mahé i, Solal ac, lévy bi, Duboc D, Simoneau g, et 
al. comparative effect of aspirin and clopidogrel on arterial 
function in chf. int J cardiol. 2006;106:61-6. Medline:16321668 
doi:10.1016/j.ijcard.2004.12.059
37 Kindsvater S, leclerc K, Ward J. effects of coadministration of 
aspirin or clopidogrel on exercise testing in patients with heart 
failure receiving angiotensin-converting enzyme inhibitors. am 
J cardiol. 2003;91:1350-2. Medline:12767432 doi:10.1016/S0002-
9149(03)00328-X
38 bonde l, Sorensen r, fosbřl el, abildstrřm SZ, hansen Pr, Kober 
l, et al. increased mortality associated with low use of clopidogrel 
in patients with heart failure and acute myocardial infarction not 
undergoing percutaneous coronary intervention: a nationwide 
study. J am coll cardiol. 2010;55:1300-7. Medline:20338489 
doi:10.1016/j.jacc.2009.11.057
39 avellana P, Segovia J, ferrero a, Vázquez r, brugada J, borrás 
X, et al. anticoagulation therapy in patients with heart failure 
due to systolic dysfunction and sinus rhythm: analysis of 
reDinScor registry. rev esp cardiol. 2012;65:705-12. engl ed. 
Medline:22464104 doi:10.1016/j.recesp.2011.11.012
40 cleland Jg, findlay i, Jafri S, Sutton g, falk r, bulpitt c, et al. The 
Warfarin/aspirin Study in heart failure (WaSh): a randomized 
trial comparing antithrombotic strategies for patients with 
heart failure. am heart J. 2004;148:157-64. Medline:15215806 
doi:10.1016/j.ahj.2004.03.010
41 cokkinos DV, haralabopoulos gc, Kostis Jb, Toutouzas PK; helaS 
investigators. efficacy of antithrombotic therapy in chronic 
heart failure: the helaS study. eur J heart fail. 2006;8:428-32. 
Medline:16737850 doi:10.1016/j.ejheart.2006.02.012
42 Massie bM, collins Jf, ammon Se, armstrong PW, cleland Jg, 
ezekowitz M, et al. randomized trial of warfarin, aspirin, and 
clopidogrel in patients with chronic heart failure: the Warfarin 
and antiplatelet Therapy in chronic heart failure (WaTch) trial. 
circulation. 2009;119:1616-24. Medline:19289640 doi:10.1161/
circulaTionaha.108.801753
43 homma S, Thompson Jl, Pullicino PM, levin b, freudenberger 
rS, Teerlink Jr, et al. Warfarin and aspirin in patients with heart 
failure and sinus rhythm. n engl J Med. 2012;366:1859-69. 
Medline:22551105 doi:10.1056/neJMoa1202299
44 homma S, Thompson Jl, Sanford ar, Mann Dl, Sacco rl, levin 
b, et al. Warcef investigators. benefit of warfarin compared 
to aspirin in patients with heart failure in sinus rhythm: a 
subgroup analysis of Warcef, a randomized controlled trial. 
circ heart fail. 2013;6:988-97. Medline:23881846 doi:10.1161/
circhearTfailure.113.000372
45 heit Ja, o’fallon WM, Petterson TM, lohse cM, Silverstein MD, 
Mohr Dn. relative impact of risk factors for deep vein thrombosis 
and pulmonary embolism: a population-based study. arch 
intern Med. 2002;162:1245-8. Medline:12038942 doi:10.1001/
archinte.162.11.1245
46 Kozdağ g, yaymacı M, ertaş g, celikyurt u, Sahin T, Kılıç T, et al. 
aspirin, clopidogrel, and warfarin use and outcomes in a cohort of 
580 patients discharged after hospitalization for decompensated 
heart failure. heart Vessels. 2012;27:568-75. Medline:21909806 
doi:10.1007/s00380-011-0185-6
47 aspirin withdrawal in non-ischaemic cardiomyopathy study. 
available from: https://clinicaltrials.gov/ct2/show/ncT01534026. 
clinicalTrials.gov identifier: ncT01534026. accessed: December 17, 
2014.
48 clopidogrel versus aspirin in chronic heart failure. available from: 
http://www.isrctn.com/iSrcTn13415258. accessed: December 17, 
2014.
49 a study to assess the effectiveness and safety of rivaroxaban 
in reducing the risk of death, myocardial infarction or stroke 
in participants with heart failure and coronary artery disease 
following hospitalization for heart failure (coMManDer hf). 
available from: ttp://clinicaltrials.gov/show/ncT01877915. 
clinicalTrials.gov identifier: ncT01877915. accessed: December 17, 
2014. 
